Bimatoprost promotes satiety and attenuates body weight gain in rats fed standard or obesity-promoting diets

Prostaglandins Leukot Essent Fatty Acids. 2022 Dec;187:102511. doi: 10.1016/j.plefa.2022.102511. Epub 2022 Nov 11.


Bimatoprost is a synthetic prostamide F analog that down-regulates adipogenesis in vitro. This effect has been attributed to participation in a negative feedback loop that regulates anandamide-induced adipogenesis. A follow-on investigation has now been conducted into the broader metabolic effects of bimatoprost using rats under both normal state and obesity-inducing conditions. Chronic bimatoprost administration attenuated weight gain in a dose dependent-manner in rats fed either standard [max effect -7%] or obesity-promoting diets [max effect -23%] over a 9-10 week period. Consistent with these findings, bimatoprost promoted satiety as measured by decreased food intake [max effect, -7%], gastric emptying [max effect, -33-50%] and decreased circulating concentrations of the gut hormones, ghrelin and GLP-1 [max effect, -33-50%]. Additionally, subcutaneous, and visceral fat mass were distinctly affected by treatment [-30% diet independent]. Taken together, these results suggest that bimatoprost regulates energy homeostasis through promoting satiety and a decrease in food intake. These newly reported activities of bimatoprost reveal an additional method of metabolic disease intervention for potential therapeutic exploitation.

Keywords: Anandamide; Bimatoprost; Obesity; Prostamide; Satiety.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adipogenesis
  • Animals
  • Bimatoprost
  • Diet
  • Obesity* / drug therapy
  • Rats
  • Weight Gain*


  • Bimatoprost